Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 1
2005 1
2006 4
2007 3
2008 3
2009 1
2010 2
2011 3
2012 3
2013 7
2014 4
2015 6
2016 4
2017 2
2018 4
2019 2
2020 3
2021 3
2022 2
2023 4
2024 6
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

63 results

Results by year

Filters applied: . Clear all
Page 1
YAP Regulates HER3 Signaling-Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers.
Katayama Y, Yamada T, Tanimura K, Kawachi H, Ishida M, Matsui Y, Hirai S, Nakamura R, Morimoto K, Furuya N, Arai S, Goto Y, Sakata Y, Nishino K, Tsuchiya M, Tamiya A, Saito G, Muto S, Takeda T, Date K, Fujisaka Y, Watanabe S, Fujimoto D, Uehara H, Horinaka M, Sakai T, Yano S, Tokuda S, Takayama K. Katayama Y, et al. Among authors: fujisaka y. Clin Cancer Res. 2025 Mar 17;31(6):1127-1141. doi: 10.1158/1078-0432.CCR-24-1762. Clin Cancer Res. 2025. PMID: 39495173
The Whole Picture of First-Line Osimertinib for EGFR Mutation-Positive Advanced NSCLC: Real-World Efficacy, Safety, Progression Pattern, and Posttreatment Therapy (Reiwa Study).
Watanabe K, Hosomi Y, Naoki K, Nakahara Y, Tsukita Y, Matsumoto H, Yoh K, Fujisaka Y, Takahashi S, Takata S, Usui K, Kishi K, Naka G, Tamano S, Uemura K, Kunitoh H. Watanabe K, et al. Among authors: fujisaka y. JTO Clin Res Rep. 2024 Sep 7;5(11):100720. doi: 10.1016/j.jtocrr.2024.100720. eCollection 2024 Nov. JTO Clin Res Rep. 2024. PMID: 39416709 Free PMC article.
Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: Results from the multicenter, phase 2 REMORA trial.
Niho S, Sato J, Satouchi M, Itoh S, Okuma Y, Mizugaki H, Murakami H, Fujisaka Y, Kozuki T, Nakamura K, Machida R, Ohe Y, Tamai T, Ikezawa H, Yamamoto N. Niho S, et al. Among authors: fujisaka y. Lung Cancer. 2024 May;191:107557. doi: 10.1016/j.lungcan.2024.107557. Epub 2024 Mar 30. Lung Cancer. 2024. PMID: 38626709 Free article. Clinical Trial.
Guidance on the short hydration method for cisplatin administration.
Ninomiya K, Kunimasa K, Kurata Y, Sato Y, Fujisaka Y, Ishikawa H, Hotta K. Ninomiya K, et al. Among authors: fujisaka y. Int J Clin Oncol. 2025 Jul;30(7):1287-1293. doi: 10.1007/s10147-025-02780-8. Epub 2025 Jun 4. Int J Clin Oncol. 2025. PMID: 40465128 Free PMC article. Review.
Overall survival analysis of patients enrolled in a randomized phase III trial comparing gefitinib and erlotinib for previously treated advanced lung adenocarcinoma (WJOG5108LFS).
Katakami N, Yokoyama T, Morita S, Okamoto T, Urata Y, Hattori Y, Iwamoto Y, Sato Y, Ikeda N, Takahashi T, Daga H, Oguri T, Fujisaka Y, Nishino K, Sugawara S, Kozuki T, Oki M, Yamamoto N, Nakagawa K. Katakami N, et al. Among authors: fujisaka y. Int J Clin Oncol. 2023 Jan;28(1):79-88. doi: 10.1007/s10147-022-02266-x. Epub 2022 Nov 21. Int J Clin Oncol. 2023. PMID: 36414827 Clinical Trial.
63 results